Osteocalcin Promotes β-Cell Proliferation During Development and Adulthood Through Gprc6a

  1. Patricia Ducy2
  1. 1Department of Genetics & Development, College of Physicians and Surgeons, Columbia University, New York, NY
  2. 2Department of Pathology & Cell Biology, College of Physicians and Surgeons, Columbia University, New York, NY
  1. Corresponding author: Patricia Ducy, pd2193{at}columbia.edu.

Abstract

Expanding β-cell mass through β-cell proliferation is considered a potential therapeutic approach to treat β-cell failure in diabetic patients. A necessary step toward achieving this goal is to identify signaling pathways that regulate β-cell proliferation in vivo. Here we show that osteocalcin, a bone-derived hormone, regulates β-cell replication in a cyclin D1–dependent manner by signaling through the Gprc6a receptor expressed in these cells. Accordingly, mice lacking Gprc6a in the β-cell lineage only are glucose intolerant due to an impaired ability to produce insulin. Remarkably, this regulation occurs during both the perinatal peak of β-cell proliferation and in adulthood. Hence, the loss of osteocalcin/Gprc6a signaling has a profound effect on β-cell mass accrual during late pancreas morphogenesis. This study extends the endocrine role of osteocalcin to the developmental period and establishes osteocalcin/Gprc6a signaling as a major regulator of β-cell endowment that can become a potential target for β-cell proliferative therapies.

  • Received June 5, 2013.
  • Accepted August 29, 2013.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

Articles citing this article

| Table of Contents

This Article

  1. Diabetes vol. 63 no. 3 1021-1031
  1. All Versions of this Article:
    1. db13-0887v1
    2. 63/3/1021 most recent